MALVERN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), announced today the issuance of a U.S.

宾夕法尼亚州马尔文，2024年7月24日（环球通讯社）--通过IBN-Annovis Bio Inc.（纽约证券交易所：ANVS）（“Annovis”或“公司”），一家晚期临床药物平台公司，开创了阿尔茨海默氏病（AD）和帕金森氏病（PD）等神经退行性疾病的转化疗法，今天宣布发布美国。

patent for methods of treating acute traumatic brain injuries (TBI) with its lead drug candidate, buntanetap.In 2016, the Company filed a patent covering the treatment of various nerve insults, including TBI, stroke, and nerve and spinal cord injuries. While these claims were granted in Europe and worldwide, the U.S.

治疗急性创伤性脑损伤（TBI）的方法专利，其主要候选药物buntanetap。2016年，该公司申请了一项专利，涵盖各种神经损伤的治疗，包括TBI，中风以及神经和脊髓损伤。。

Patent and Trademark Office (USPTO) required the claims to be divided into individual patents for each indication. Annovis Bio has now received U.S. Patent No. 12,042,482, which covers methods for treating TBI and preventing nerve cell death with buntanetap.“We are thrilled to achieve this significant milestone for buntanetap,” said Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis.

美国专利商标局（USPTO）要求将权利要求划分为每个指示的单独专利。Annovis Bio现已获得美国专利号12042482，该专利涵盖了用buntanetap治疗TBI和预防神经细胞死亡的方法。Annovis创始人、总裁兼首席执行官玛丽亚·麦克切奇尼博士表示：“我们很高兴能为buntanetap取得这一重要里程碑。”。

“Nerve cell death is a common underlying factor in many brain conditions, beyond just Alzheimer’s and Parkinson’s. Our preclinical studies in TBI and stroke animal models have demonstrated buntanetap’s efficacy in preventing cell death and loss of function, and it is our duty to explore its potential benefits for victims of brain trauma, a prevalent issue in the U.S.”This patent significantly strengthens Annovis Bio’s portfolio which includes patents and patent applications covering the use of buntanetap for acute and chronic neurodegenerative diseases as well as mental illnesses.

“除了阿尔茨海默氏症和帕金森氏症之外，神经细胞死亡是许多脑部疾病的常见潜在因素。我们在TBI和中风动物模型中的临床前研究已经证明了布坦塔普在预防细胞死亡和功能丧失方面的功效，我们有责任探索其对脑创伤受害者的潜在益处，这是美国的一个普遍问题。”这项专利大大加强了Annovis Bio的投资组合，其中包括专利和专利申请，涵盖了布坦塔普在急性和慢性神经退行性疾病以及精神疾病中的使用。

The Company's commitment to addressing a broad range of neurodegenerative [MM1] disorders highlight its innovative approach to restoring brain function and im.

该公司致力于解决广泛的神经退行性疾病，突出了其恢复大脑功能和im的创新方法。